The Goldman Sachs Group Initiates Coverage on Generate Biomedicines (NASDAQ:GENB)

Key Points

• Goldman Sachs initiated coverage on Generate Biomedicines (GENB) with a buy rating and a $26 price target, implying about a 107.7% upside from the prior close.
• Other firms including Guggenheim (buy, $30 target) and Cantor Fitzgerald (overweight) also began coverage, and MarketBeat reports an average analyst rating of Buy with a $25 average price target.
• Generate Biomedicines applies machine learning and generative AI to design novel therapeutics, and its stock recently opened at $12.52, trading in a 12‑month range of $11.00 to $15.32.

Research analysts at The Goldman Sachs Group began coverage on shares of Generate Biomedicines (NASDAQ:GENB - Get Free Report) in a research report issued on Tuesday. The brokerage set a "buy" rating and a $26.00 price target on the stock. The Goldman Sachs Group's price objective would indicate a potential upside of 107.67% from the company's previous close.

Several other research firms have also issued reports on GENB. Wall Street Zen upgraded shares of Generate Biomedicines to a "hold" rating in a report on Saturday, March 14th. Guggenheim assumed coverage on shares of Generate Biomedicines in a research report on Tuesday. They set a "buy" rating and a $30.00 price objective for the company. Finally, Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research note on Tuesday. They set an "overweight" rating for the company. Five research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $25.00.

Generate Biomedicines Price Performance

GENB stock opened at $12.52 on Tuesday. Generate Biomedicines has a 12 month low of $11.00 and a 12 month high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc NASDAQ: GENB is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.